Resistance to cytarabine and anthracycline-based chemotherapy is a major cause of treatment failure in AML.10 More precisely, CD34+CD38− leukemic cell population, enriched in LSCs, are highly resistant to these and other conventional chemotherapies.21 Therefore new therapies are urgently needed for this deadly disease. The gene discussed is CD38; the disease is acute myeloid leukemia.